BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12632766)

  • 1. [Prognostic impact of karyotype in de novo acute myeloid leukemia: study of 139 cases].
    Sennana Sendi H; Elghezal H; Temmi H; Gribaa M; Laatiri A; Ben Abid H; Ben Abdeladhime A; Elloumi M; Hafsia A; Saad A
    Tunis Med; 2002 Sep; 80(9):531-5. PubMed ID: 12632766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.
    Dastugue N; Payen C; Lafage-Pochitaloff M; Bernard P; Leroux D; Huguet-Rigal F; Stoppa AM; Marit G; Molina L; Michallet M
    Leukemia; 1995 Sep; 9(9):1491-8. PubMed ID: 7658718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
    Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
    Perea G; Domingo A; Villamor N; Palacios C; Juncà J; Torres P; Llorente A; Fernández C; Tormo M; Queipo de Llano MP; Bargay J; Gallart M; Florensa L; Vivancos P; Martí JM; Font L; Berlanga J; Esteve J; Bueno J; Ribera JM; Brunet S; Sierra J; Nomdedéu JF;
    Leuk Res; 2005 Oct; 29(10):1109-16. PubMed ID: 16095690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
    Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
    Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
    Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
    J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.
    Damiani D; Tiribelli M; Raspadori D; Michelutti A; Gozzetti A; Calistri E; Candoni A; Chiarvesio A; Lenoci M; Russo D; Fanin R
    Hematol Oncol; 2007 Mar; 25(1):38-43. PubMed ID: 17200981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival.
    Arber DA; Stein AS; Carter NH; Ikle D; Forman SJ; Slovak ML
    Am J Clin Pathol; 2003 May; 119(5):672-80. PubMed ID: 12760285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of cytogenetics in acute myeloid leukemia.
    Mrózek K; Heinonen K; de la Chapelle A; Bloomfield CD
    Semin Oncol; 1997 Feb; 24(1):17-31. PubMed ID: 9045301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
    Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
    Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities.
    Chen CC; Yang CF; Lee KD; You JY; Yu YB; Ho CH; Tzeng CH; Chau WK; Hsu HC; Gau JP
    Cancer Genet Cytogenet; 2007 Apr; 174(2):138-46. PubMed ID: 17452256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
    Blum W; Mrózek K; Ruppert AS; Carroll AJ; Rao KW; Pettenati MJ; Anastasi J; Larson RA; Bloomfield CD
    Cancer; 2004 Sep; 101(6):1420-7. PubMed ID: 15368330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adapted induction and consolidation therapy in adults with de novo AML aged Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A
    Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic, morphological, and immunophenotypic patterns in Omani patients with de novo acute myeloid leukemia.
    Udayakumar AM; Pathare AV; Al-Kindi S; Khan H; Rehmen JU; Zia F; Al-Ghazaly A; Nusrut N; Khan MI; Wali YA; Al-Lamki Z; Dennison D; Raeburn JA
    Cancer Genet Cytogenet; 2007 Sep; 177(2):89-94. PubMed ID: 17854660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.